New Chemo - Free Immunotherapy Options For NSCLC
from OncoPharm Hosted by John Bossaer
There are 2 new Immunotherapy (without chemo) options for untreated metastatic NSCLC. We try to make sense of this evolving landscape. Then, we run through the latest TKI, ripretinib. Finally, we discuss a new approval for Kaposi sarcoma and our obligatory PARP inhibitors update of the week.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 16 minutes long.
When was this OncoPharm episode published?
This episode was published on May 21, 2020.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.